CAMBRIDGE, MASS.-The growth rate in medical costs for MCOs in 2006 will decrease marginally compared with 2005 as a result of continued efforts to control costs, according to a MedPanel Inc. survey of managed care medical directors representing about 30 million U.S. lives.
CAMBRIDGE, MASS.-The growth rate in medical costs for MCOs in 2006 will decrease marginally compared with 2005 as a result of continued efforts to control costs, according to a MedPanel Inc. survey of managed care medical directors representing about 30 million U.S. lives.
"While managed care executives anticipated a rise in overall costs between 2005 and 2006, the rate of increase was expected to be slightly lower than the increase seen from 2004 to 2005," says Stephen Bubb, senior director, quantitative services at MedPanel, a global online research firm. Managed care medical directors in MedPanel's 2006 and 2004 surveys predicted medical cost growth rates of 10.4% and 10.9%, respectively.
In the 2006 survey, the majority of medical directors (68%) indicated that managing specialty pharmacy costs is a high priority. Further, MCOs are expected to adopt health-plan designs that shift decision-making to consumers.
In the current environment, MCOs have no choice but to continue aggressive attempts to control pharmacy costs and minimize hospital utilization rates, according to Matt Fearer, senior vice president, MedPanel. "Strategic investment in persistency and compliance programs and prevention initiatives will remain critically important, particularly for suppressing rates of hospitalization. Increased cost-sharing for patients appears inevitable," Fearer says. "As MCOs introduce consumer-driven products, we encourage them to focus on educational programs that help consumers to make informed healthcare purchasing decisions."
FDA Site Inspections Decreased During Pandemic. Questions Continue about Drug Quality.
December 4th 2023A recent study has found that FDA inspections of drug manufacturing facilities have increased since the COVID-19 health emergency but have not yet returned to pre-pandemic numbers.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
RSV Vaccines for Adults: Gaps in Understanding
December 4th 2023Angela Branche, M.D., an infectious disease specialist at the University of Rochester School of Medicine, says the gaps are in a precise understanding of who is at risk for serious illness from respiratory syncytial virus and therefore who should get vaccinated.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen